Neumora Therapeutics, Inc. (NMRA) Tops Q4 EPS by 25c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
Go back to Neumora Therapeutics, Inc. (NMRA) Tops Q4 EPS by 25c
March 3, 2025 1:15 PM EST
Guggenheim analyst Yatin Suneja reiterated a Buy rating and $7.00 price target on Neumora Therapeutics (NASDAQ: NMRA)
The analyst comments "Key Message: Today NMRA reported 4Q24 financial results and pipeline updates. Our key highlights include: (1) NMRA has paused KOASTAL-2 and -3 studies of navacaprant (KOR antagonist) and plans to resume them in March 2025 after implementing a series of optimizations based on learnings from KOASTAL-1 (K-1; recall this study failed the primary endpoint - see HERE and HERE), including enhanced... More
March 3, 2025 9:16 AM EST
Stifel analyst Paul Matteis lowered the price target on Neumora Therapeutics (NASDAQ: NMRA) to $6.00 (from $26.00) while maintaining a Buy rating.
The analyst comments "We remain Buy rated on NMRA, as we think the risk/reward on the KOSTAL-2/3 trials is... More
